Clavaseptin 50mg ízesített tablett
Gysz:8C1803E Lej:20/06/04
Kisz:10x Me.:darab
DR. SZÉKELY KFT. részére

2151 Fót
Keleti Márton u. 19.
Tel:27/537-100
Fax:27/537-100

vetoquinol
ACHIEVE MORE TOGETHER

CERTIFICATE OF ANALYSIS

FINISHED PRODUCT

Product name : CLAVASEPTIN 50 10 CY HU RO
Analytical code : 426052
Manufacturing date : 05/06/2018
Pharmaceutical form : Not Coated Tablets
Expiration date : 04/06/2020
Batch number : 8C1803E

TESTS	SPECIFICATIONS	RESULTS
Characteristics of tablets	Oblong, off-white to brownish sprinkled, scored	Pass
Length	>= 9.8 <= 10.2 mm	10.1 mm
Average weight and uniformity of weight		
Average mass	>= 90.4 <= 100.0 mg	95.2 mg
Uniformity of mass	Complies with Eur. Ph. 2.9.5.	Pass
Resistance to crushing	>= 30 N	41 N
Disintegration test	<= 15 min	<4 min
Equilibrium relative humidity	<= 15 %	14 %
Amoxicillin dissolution rate	Q=85% within 30 min	101 %
Amoxicilin dissolution compliance	Complies with EP 2.9.3.	Pass
Clavulanic ac dissolution rate	Q=80% within 30 min	102 %
Clavulanic ac dissolution compliance	Complies with EP 2.9.3.	Pass
Amoxicillin and clavulanic acid identity (HPLC)		
Amoxicillin UV spectrum	Positive	Pass
Amoxicillin retention time	Positive	Pass
Clavulanic acid UV spectrum	Positive	Pass
Clavulanic acid retention time	Positive	Pass
Amoxicillin and clavulanic acid assay		
Amoxicillin content	>= 38.00 <= 42.00 mg/tablet	40.29 mg/tab.
Clavulanic acid content	>= 9.78 <= 10.82 mg/tablet	9.86 mg/tab.

This document has been produced electronically and is valid without a signature.

LABORATOIRE PHARMACEUTIQUE VÉTÉRINAIRE
Magny-Vernois | B.P.189 | 70204 Lure Cedex (France) | TÉL. : +33 (0) 3 84 62 55 55 - FAX : +33 (0) 3 84 62 55 56
VETOQUINOL S.A. au Capital de 29.704.755 € | SIRET 676 250 111 00017 | RCS VESOUL GRAY B 676 250 111

vetoquinol
ACHIEVE MORE TOGETHER

CERTIFICATE OF ANALYSIS

FINISHED PRODUCT

Product name :	CLAVASEPTIN 50 10 CY HU RO	**Analytical code :**	426052
Pharmaceutical form :	Not Coated Tablets	**Manufacturing date :**	05/06/2018
Batch number :	8C1803E	**Expiration date :**	04/06/2020

TESTS	SPECIFICATIONS	RESULTS
Amoxicillin purity (HPLC)		
Imp.A	<= 1.0 %w/w	<0.3 % w/w
Imp.B	<= 1.0 %w/w	<0.3 % w/w
Imp.C	<= 1.0 %w/w	<0.3 % w/w
Imp.D	<= 1.0 %w/w	0.3 % w/w
Imp.E	<= 1.0 %w/w	<0.3 % w/w
Imp.F	<= 1.0 %w/w	0.5 % w/w
Imp.G	<= 1.0 %w/w	0.5 % w/w
Imp.K	<= 1.0 %w/w	<0.3 % w/w
Any unidentified degradation product	<= 1.0 %w/w	<0.3 % w/w
Total unidentified degradation products	<= 2.0 %w/w	<0.3 % w/w
Total degradation products	<= 3.0 %w/w	1.2 % w/w
Clavulanic acid impurities (HPLC)		
Any unspecified degradation product	<= 1.0 %area	<0.3 % area
Total degradation products	<= 2.0 %area	<0.3 % area

I hereby certify that this lot is manufactured, packed and labelled under conditions as stated in the current European Union rules for Good Manufacturing Practice for medicinal products for veterinary use, and that the finished product in all aspects answers the requirements laid down in the marketing authorisation.

Released by Qualified Person :	Paul-Adrien MATHON
Date :	08/10/2018 12:00:14
Decision :	FULL RELEASE

This document has been produced electronically and is valid without a signature.

LABORATOIRE PHARMACEUTIQUE VÉTÉRINAIRE

Magny-Vernois | B.P.189 | 70204 Lure Cedex (France) | TÉL. : +33 (0) 3 84 62 55 55 - FAX : +33 (0) 3 84 62 55 56
VETOQUINOL S.A. au Capital de 29.704.755 € | SIRET 676 250 111 00017 | RCS VESOUL GRAY B 676 250 111